HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.
about
Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A VirusResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceRapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader AssayRandomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionGenetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in JapanRapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.Faldaprevir for the treatment of hepatitis C.Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.Analysis of significantly mutated genes as a clinical tool for the diagnosis in a case of lung cancer.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVSimeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants.Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation.APASL consensus statements and recommendation on treatment of hepatitis C.Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort.
P2860
Q26775640-9D304B4F-18E1-4A39-A794-B2D5E95C52F0Q26777408-756CC0C2-98C7-421B-BB0D-3FDAD2D46AC9Q27469038-4CB14020-6B30-4A8C-AA34-CF5E859DC9AAQ28548426-D6E266E7-2BE8-482F-BB07-7C483FEC5502Q36014286-8E9E56CC-3283-4610-B5C7-48CBFD30F56DQ36096436-5DACFE51-37EC-4D6A-BAE8-F76652F891AFQ36173242-1F96CEB4-5C4D-4FAC-A103-D01CAF71BBBAQ36970046-5AC1040B-06E4-4A03-920C-6E0FA64912DCQ37590179-27193D16-291B-405B-A61D-CC68C4AFC376Q38370056-D8C4B7C1-66B6-4DB9-8339-85007C2F90F1Q38860565-0B82081E-E29F-4166-B435-48F1252E4E3AQ38919473-8F392A0B-0440-4FD2-B782-FF9AE46EDD8DQ40228687-056908B4-64A0-44BD-86E7-1FC116262DFCQ40353248-50DC5608-D5F5-4FB4-8449-6154E8D4D10FQ40589672-79AC1150-C4ED-499C-977D-0F0AA4CB442AQ40923578-E04BC109-D997-41AD-A773-3D41F846CA6EQ42400012-7B422C1D-C7A2-41E4-B4EB-93F8C65568A3Q47121490-50AE642C-288E-4729-BD45-EF0C8F7DCD14Q53690933-9DA41E08-CD05-42DC-9F90-611B9D187DEC
P2860
HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
HCV NS5A resistance-associated ...... infected with HCV genotype 1b.
@en
type
label
HCV NS5A resistance-associated ...... infected with HCV genotype 1b.
@en
prefLabel
HCV NS5A resistance-associated ...... infected with HCV genotype 1b.
@en
P2093
P2860
P1476
HCV NS5A resistance-associated ...... infected with HCV genotype 1b.
@en
P2093
Hiroshi Matsumura
Masao Omata
Mitsuhiko Moriyama
Osamu Yokosuka
Tatsuo Kanda
Yosuke Hirotsu
P2860
P2888
P304
P356
10.1007/S12072-015-9624-2
P577
2015-03-20T00:00:00Z